Target intelligence / Profile preview

Nicotinic acetylcholine receptor alpha4beta2 (α4β2 nAChR)

Target
α4β2 nAChR
Molecular classification
Ion channel, Ligand-gated ion channel, Pentameric receptor, Cys-loop receptor
01

Overview

The nicotinic acetylcholine receptor alpha4beta2 (α4β2 nAChR) is a heteropentameric ligand-gated ion channel that mediates fast chemical neurotransmission in the brain. As the most abundant nicotinic subtype in the brain, it plays crucial roles in cognitive function, learning, and various neurological processes. The receptor exists in two stoichiometries with different sensitivities to nicotine and calcium permeability. It is the primary target for nicotine's addictive properties and is implicated in several neurological disorders including Parkinson's disease, Alzheimer's disease, and schizophrenia. The receptor's structure has been determined by X-ray crystallography, revealing insights into its complex architecture and function. Pharmacologically, it can be targeted by various agonists, antagonists, and positive allosteric modulators, making it an important therapeutic target for neurological and psychiatric conditions. Recent research has focused on developing subtype-selective compounds that can modulate α4β2 nAChR function with minimal side effects.

Other names
Alpha-4 beta-2 nicotinic receptorα4β2 receptorHeteromeric α4β2 nicotinic receptor
02

Mechanism of action

Agonism - direct activation of the receptor leading to cation influx; Positive allosteric modulation - enhancing the effect of endogenous agonists; Antagonism - blocking receptor activation

03

Biological functions

Signal transductionNeurotransmissionCognitive functionLearning and memoryRegulation of neurotransmitter releaseGrowth hormone secretion
04

Disease associations

Neurodegenerative diseases (Parkinson's disease, Alzheimer's disease)Addiction (particularly nicotine addiction)SchizophreniaCognitive disordersInflammatory conditions
05

Safety considerations

Side effects associated with broad cholinergic activationPotential for addiction with certain agonists (e.g., nicotine)Challenges in achieving subtype selectivity
06

Interacting drugs

Nicotine

7 more in the full profile.

07

Biomarkers

Receptor expression levelsReceptor stoichiometry ((α4)2(β2)3 vs. (α4)3(β2)2)Binding affinity for specific ligands

Beyond the preview

Go deeper on Nicotinic acetylcholine receptor alpha4beta2 (α4β2 nAChR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nicotinic acetylcholine receptor alpha4beta2 (α4β2 nAChR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call